Open AccessValidation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment
Author(s) -
Pınar Gökçen,
Fatih Güzelbulut,
Gupse Adalı,
Ayca Gokce Degirmenci Salturk,
Oğuzhan Öztürk,
Özgür Bahadır,
Emine Kanatsız,
Mevlüt Kıyak,
Kamil Özdil,
Levent Doganay
Publication year - 2022
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v28.i6.665
Subject(s) - entecavir , medicine , hepatocellular carcinoma , hepatitis b virus , hepatitis b , receiver operating characteristic , framingham risk score , logistic regression , gastroenterology , risk factor , oncology , immunology , virus , lamivudine , disease
Several risk scores have been developed to predict hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients. The majority of risk scores are based on pretreatment variables that are no longer considered risk factors for HCC development due to the suppression of hepatitis B virus replication early in the course of potent antiviral treatment in most patients. The PAGE-B score, which is based on platelet levels, age and sex, has been shown to accurately predict HCC risk in CHB patients on antiviral treatment in various populations.